Neurogene Inc. Proceeds from (Repurchase of) Redeemable Preferred Stock
Neurogene Inc. (NGNE) reported Proceeds from (Repurchase of) Redeemable Preferred Stock of -$590 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-03-16.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRepurchaseOfRedeemablePreferredStock · last filed 2016-03-14
- Neurogene Inc. proceeds from (repurchase of) redeemable preferred stock for the quarter ending 2014-12-31 was $0.00, a 100.00% decline year-over-year.
- Neurogene Inc. proceeds from (repurchase of) redeemable preferred stock for the quarter ending 2014-09-30 was -$99.00, a 1514.29% decline year-over-year.
- Neurogene Inc. proceeds from (repurchase of) redeemable preferred stock for the quarter ending 2014-06-30 was $0.00.
- Neurogene Inc. proceeds from (repurchase of) redeemable preferred stock for the quarter ending 2014-03-31 was -$491.00, a 100.00% decline year-over-year.
- Neurogene Inc. proceeds from (repurchase of) redeemable preferred stock for fiscal 2014 was -$590.00, a 100.00% decline from fiscal 2013.
- Neurogene Inc. proceeds from (repurchase of) redeemable preferred stock for fiscal 2013 was $18.00M.
| Period end | Proceeds from (Repurchase of) Redeemable Preferred Stock 3 month | Proceeds from (Repurchase of) Redeemable Preferred Stock 6 month | Proceeds from (Repurchase of) Redeemable Preferred Stock 9 month | Proceeds from (Repurchase of) Redeemable Preferred Stock 12 month | Proceeds from (Repurchase of) Redeemable Preferred Stock 12 month as first filed | Proceeds from (Repurchase of) Redeemable Preferred Stock 123 month |
|---|---|---|---|---|---|---|
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | -$99.00 derived: sum of 2 quarters · filed 2015-03-16 | -$99.00 derived: sum of 3 quarters · filed 2015-03-16 | -$590.00 10-K · filed 2015-03-16 | ||
| 2014-09-30 | -$99.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | -$99.00 derived: sum of 2 quarters · filed 2014-11-04 | -$590.00 10-Q · filed 2014-11-04 | $2.44K derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | -$491.00 10-Q · filed 2014-08-11 | $2.54K derived: sum of 3 quarters · filed 2016-03-14 | $2.55K derived: sum of 4 quarters · filed 2016-03-14 | ||
| 2014-03-31 | -$491.00 10-Q · filed 2014-05-13 | $2.54K derived: sum of 2 quarters · filed 2016-03-14 | $2.55K derived: sum of 3 quarters · filed 2016-03-14 | $2.55K derived: sum of 4 quarters · filed 2016-03-14 | $57.84M 10-Q · filed 2014-05-13 | |
| 2013-12-31 | $3.03K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-14 | $3.04K derived: sum of 2 quarters · filed 2016-03-14 | $3.04K derived: sum of 3 quarters · filed 2016-03-14 | $18.00M 10-K · filed 2016-03-14 | $18.00M 10-K · filed 2015-03-16 | |
| 2013-09-30 | $7.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-04 | $7.00 derived: sum of 2 quarters · filed 2014-11-04 | $18.00M 10-Q · filed 2014-11-04 | |||
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $18.00M 10-Q · filed 2014-08-11 | ||||
| 2013-03-31 | $18.00M 10-Q · filed 2014-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |